Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer

(2013) Andrea Lunardi et al.   NATURE GENETICS

Recommendations for imaging tumor response in neurofibromatosis clinical trials

(2013) E. Dombi et al.   NEUROLOGY

Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition

(2012) Carlos E. Prada et al.   ACTA NEUROPATHOLOGICA

Sensitivity of Glioblastomas to Clinically Available MEK Inhibitors Is Defined by Neurofibromin 1 Deficiency

(2012) W. L. See et al.   CANCER RESEARCH

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice

(2012) Tiffany Chang et al.   JOURNAL OF CLINICAL INVESTIGATION

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors

(2012) Walter J. Jessen et al.   JOURNAL OF CLINICAL INVESTIGATION

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial

(2012) Kent A Robertson et al.   LANCET ONCOLOGY

Frequency-Modulated Pulses of ERK Activity Transmit Quantitative Proliferation Signals

(2012) John G. Albeck et al.   MOLECULAR CELL

Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1

(2012) Rosa Nguyen et al.   Orphanet Journal of Rare Diseases

Elucidating Distinct Roles for NF1 in Melanomagenesis

(2012) Ophélia Maertens et al.   Cancer Discovery

Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system

(2011) Nicole M. Brossier et al.   BRAIN RESEARCH BULLETIN

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

(2011) Peter D. Boasberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors

(2011) Eline Beert et al.   GENES CHROMOSOMES & CANCER

Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1

(2011) Carlos E. Prada et al.   JOURNAL OF PEDIATRICS

Phase I trial of pegylated interferon- -2b in young patients with plexiform neurofibromas

(2011) R. I. Jakacki et al.   NEUROLOGY

Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

(2011) Jianqiang Wu et al.   PEDIATRIC BLOOD & CANCER

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

(2010) E. B. Haura et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Clinical and genetic aspects of neurofibromatosis 1

(2010) Kimberly Jett et al.   GENETICS IN MEDICINE

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

PD0325901, a Mitogen-Activated Protein Kinase Kinase Inhibitor, Produces Ocular Toxicity in a Rabbit Animal Model of Retinal Vein Occlusion

(2009) Wenhu Huang et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas

(2009) A. Kim et al.   NEUROLOGY

Plexiform and Dermal Neurofibromas and Pigmentation Are Caused by Nf1 Loss in Desert Hedgehog-Expressing Cells

(2008) Jianqiang Wu et al.   CANCER CELL

Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone Marrow

(2008) Feng-Chun Yang et al.   CELL